SCHEMBL4314030

SCHEMBL4314030

N[C@@H](COS(=O)(=O)O)C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.41
SLC7A11 Q9UPY5 1/20 0.41
PMP22 Q01453 2/20 0.41
SLC1A1 P43005 4/20 0.38
SLC1A3 P43003 3/20 0.38
SLC1A2 P43004 3/20 0.38
GSR P00390 2/20 0.38
GRIK1 P39086 2/20 0.38
GRIK2 Q13002 2/20 0.38
GRM1 Q13255 2/20 0.38
GRM2 Q14416 2/20 0.38
SLC7A5 Q01650 1/20 0.38
GRM8 O00222 1/20 0.38
GRM6 O15303 1/20 0.38
GRIN2D O15399 1/20 0.38
GRIN3B O60391 1/20 0.38
CYP1A2 P05177 1/20 0.38
GRM5 P41594 1/20 0.38
GRIA1 P42261 1/20 0.38
GRIA2 P42262 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2289857 1.00 PTGS1 (0.41) PTGS1SLC7A11PMP22SLC1A1SLC1A3
SCHEMBL28260292 0.80 PMP22 (0.48) PTGS1SLC7A11PMP22SLC1A1SLC1A3
SCHEMBL21933072 0.78 PMP22 (0.47) PMP22SLC1A1SLC1A3SLC1A2GSR
Methane SCHEMBL1237673 0.77 PMP22 (0.46) PMP22SLC1A1SLC1A3SLC1A2GSR
SCHEMBL8329628 0.75 CA2 (0.33)
Cysteine SCHEMBL28050905 0.75 PTGS1 (0.50) PTGS1SLC7A11PMP22SLC1A1
SCHEMBL3380958 0.75 GRIK1 (0.39) PTGS1SLC7A11PMP22SLC1A1SLC1A3
SCHEMBL6037154 0.74 PGK1 (0.45)
SCHEMBL31307678 0.74 NOS3 (0.43) PTGS1SLC7A11PMP22SLC1A1SLC1A3
SCHEMBL31307649 0.74 NOS3 (0.43) PTGS1SLC7A11PMP22SLC1A1SLC1A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1489 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026101240-A1 CODON OPTIMIZATION TECHNOLOGY FOR HIGH GENE EXPRESSION AND APPLICATIONS THEREOF 포항공과대학교 산학협력단 2026-05-15 WO claimed
EP-3807293-B1 PEPTIDES HAVING INHIBITORY ACTIVITY ON NEURONAL EXOCYTOSIS ACRAF (IT) 2026-01-14 EP claimed
US-20250332246-A1 ENHANCED EXPRESSION VIA AUTOTRANSPORTERS UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2025-10-30 US claimed
US-20250281535-A1 ANTI-HUMAN CD45RC BINDING DOMAINS AND USES THEREOF ABOLERIS PHARMA (FR) 2025-09-11 US claimed
WO-2025136053-A1 NATRIURETIC PEPTIDE ANALOG AND USES THEREOF 주식회사 펩트론 2025-06-26 WO claimed
WO-2025108310-A1 METHOD FOR PREPARING HETEROLOGOUS MULTIMER BY MEANS OF RECOMBINATION REACTION 江苏恒瑞医药股份有限公司 2025-05-30 WO claimed
WO-2025103680-A1 DETERGENTS AND CLEANING AGENTS COMPRISING LIGNIN DERIVATIVES HENKEL AG & CO. KGAA (DE) 2025-05-22 WO claimed
US-20250136693-A1 Anti-PD-1 Antibodies and Fusion Proteins KADMON CORPORATION, LLC (US) 2025-05-01 US claimed
WO-2025082461-A1 POLYPEPTIDE, BIOACTIVE CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF 优洛生物(上海)有限公司 2025-04-24 WO claimed
US-12258408-B2 Oncolytic virus expressing PD-1 binding protein and application of oncolytic virus SHANGHAI YUANSONG BIOTECHNOLOGY CO. LTD. (CN) 2025-03-25 US claimed
CN-118530315-A Truncated Zika virus capsid protein or variant thereof 深圳市第三人民医院(深圳市肝病研究所) 2024-08-23 CN claimed
EP-2752200-B1 ANTIGEN-BINDING MOLECULE INDUCING IMMUNE RESPONSE TO TARGET ANTIGEN CHUGAI PHARMACEUTICAL CO LTD (JP) 2023-11-01 EP claimed
CN-116660543-A Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof 中国人民解放军陆军军医大学第一附属医院 2023-08-29 CN claimed
US-20230159967-A1 FUNCTIONALISED POLSULPHIDE SYNTHESIS METHOD ARKEMA FRANCE (FR) 2023-05-25 US claimed
US-20230073411-A1 HOMODIMER-TYPE BISPECIFIC ANTIBODY AGAINST HER2 AND CD3 AND USE THEREOF AMPSOURCE BIOPHARMA SHANGHAI INC. (CN) 2023-03-09 US claimed
WO-2023006125-A1 USE OF SE-DR AFFINITY PEPTIDE IN PREPARING DRUG FOR TREATING RHEUMATIC DISEASE 河北菲尼斯生物技术有限公司 2023-02-02 WO claimed
WO-2023277575-A1 NOVEL CELL-PENETRATING PEPTIDE AND USE THEREOF 주식회사 아임뉴런 2023-01-05 WO claimed
WO-2023277628-A1 NOVEL CELL-PENETRATING PEPTIDE AND USE THEREOF 주식회사 아임뉴런 2023-01-05 WO claimed
CN-111187606-B Surfactant for seawater-based recyclable clean fracturing fluid and preparation method thereof 江苏海洋大学 2022-06-14 CN claimed
US-20200149080-A1 FUNCTIONALISED CYCLIC DITHIOCARBAMATE SYNTHESIS METHOD ARKEMA FRANCE (FR) 2020-05-14 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200149080-A1 FUNCTIONALISED CYCLIC DITHIOCARBAMATE SYNTHESIS METHOD TST, DTYMK, DDO PTGS1 1486/4885SLC7A11 650/4885PMP22 3349/4885
US-20230159967-A1 FUNCTIONALISED POLSULPHIDE SYNTHESIS METHOD POLH, POLD1, POLR2H PTGS1 2456/4885SLC7A11 2768/4885PMP22 2235/4885
US-12258408-B2 Oncolytic virus expressing PD-1 binding protein and application of oncolytic virus PDCD1LG2, CD274, PDCD1 PTGS1 3962/4885SLC7A11 4101/4885PMP22 2491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.